Federal lawsuits claiming that Pfizer’s drug Lipitor caused patients to develop Type 2 diabetes are moving forward in federal court. Cases have been consolidated in federal court in South Carolina. The United States Judicial Panel on Multidistrict Litigation (“JPML”) issued an order centralizing all associated personal injury actions into IN RE: Lipitor (Atorvastatin Calcium) Marketing, Sales Practices and Products Liability Litigation (No. II), MDL No. 2502. This order directs that all related federal lawsuits be transferred to the United States District Court of South Carolina and assigned to the Honorable Judge Richard M. Gergel for consolidated pretrial proceedings.
According to court documents, Pfizer “failed to warn physicians and consumers adequately of the risk of developing Type 2 diabetes from taking Lipitor,” and “negligently, recklessly, and/or carelessly marketed Lipitor without adequate instructions or warnings.”
Plaintiffs who filed Lipitor lawsuits against Pfizer allege that taking Lipitor caused them to develop Type 2 diabetes. The U.S. Food and Drug Administration (FDA) reported that there were serious health risks associated with taking Lipitor, which is commonly prescribed to manage high cholesterol levels. Type 2 diabetes was one of the serious health risks that the FDA communication warned of. Prior to the FDA’s warning, the label of Lipitor failed to advise patients of that serious risk.
Cory Watson Attorneys is representing clients who were injured by Lipitor.
Never stop taking any medication without first consulting your doctor.
Lipitor® is a registered trademark of Pfizer, Inc. and is used here only to identify the product in question. This law firm is not associated with, sponsored by, or affiliated with Pfizer, Inc. or the U.S. Food and Drug Administration.